Genotype and ancestry modulate brain's DAT availability in healthy humans

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• The dopamine transporter (DAT) regulates neurotransmission; its gene, SLC6A3, is linked to neurological disorders.
• Previous studies on SLC6A3 polymorphisms and behavioral phenotypes show inconsistent results.
• Objective brain measures, like imaging, may improve genotype-phenotype association detection.

Purpose of the Study:

• To investigate the relationship between dopamine transporter (DAT) brain availability and SLC6A3 genotypes.
• To utilize brain imaging data to clarify DAT genotype-phenotype associations.

Main Methods:

• Positron emission tomography (PET) with [¹¹C]cocaine was used to estimate DAT availability (Bmax/Kd).
• Genotype data were collected for two SLC6A3 polymorphisms: 3-UTR and intron 8 VNTRs.
• An aggregate sample of 95 healthy participants from multiple imaging studies was analyzed.

Main Results:

• Both 3-UTR and intron 8 polymorphisms, individually and as a haplotype, modulate midbrain DAT density.
• Ethnic background and age significantly influence the strength of these DAT genotype-phenotype associations.
• Age-related changes in DAT availability vary across different SLC6A3 genotype groups.

Conclusions:

• SLC6A3 polymorphisms are associated with variations in midbrain dopamine transporter density.
• The influence of these genetic variations on DAT availability is moderated by age and ethnicity.
• Understanding these interactions is crucial for linking SLC6A3 genotypes to neurological and behavioral phenotypes.